Meeting
2013 ASCO Annual Meeting
Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.
Authors
Meta Diekstra
Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands
Meta Diekstra , Heinz Josef Klümpen , Martijn P. J. K. Lolkema , Huixin Yu , Jacqueline S.L. Kloth , Hans Gelderblom , Ron H.N. van Schaik , Howard Gurney , Jesse J Swen , Alwin D.R. Huitema , Neeltje Steeghs , Ron H.J. Mathijssen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4580)
DOI
10.1200/jco.2013.31.15_suppl.4580
Abstract #
4580
Poster Bd #
32H
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).
First Author: Yuksel Urun
Poster
2011 ASCO Annual Meeting
Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.
First Author: J. Garcia-Donas
Poster
2018 ASCO Annual Meeting
The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.
First Author: Michael Michael
Poster
2017 Genitourinary Cancers Symposium
The impact of UGT1A1 and SLCO1B1 genetic polymorphisms and pharmacokinetics of axitinib on clinical safety and efficacy in patients with metastatic renal cell carcinoma.
First Author: Shintaro Narita